Navigation Links
Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
Date:8/6/2013

SAN DIEGO, Aug. 6, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced business and financial results for the second quarter ended June 30, 2013.

Orexigen also announced its plan to submit a Marketing Authorization Application (MAA) for Contrave® to the European Medicines Agency (EMA) utilizing the centralized procedure. Orexigen has met with the European rapporteurs to discuss the filing strategy of the MAA. Both were supportive of the company's plan to submit the application in advance of the Light Study interim analysis and to have cardiovascular outcomes data from the Light Study available for the Committee for Medicinal Products for Human Use (CHMP) Day 120 List of Questions.

"We are pleased with recent progress toward the Contrave MAA for Europe. From our interactions with multiple regulatory authorities in Europe, including with the assigned rapporteur and co-rapporteur, we believe European regulators recognize the need for new obesity therapeutics and support our plans for submission of the Contrave MAA," said Michael Narachi, Chief Executive Officer of Orexigen.

Narachi continued: "We remain focused on diligent execution of the Light Study, submission of the MAA within the next few months and resubmission of the NDA shortly after the interim analysis, which we continue to expect in the remaining months of 2013."

For the three months ended June 30, 2013, Orexigen reported a net loss of $18.2 million, or $0.19 per share, as compared to a net loss of $16.7 million, or $0.25 per share, for the second quarter of 2012.

Total operating expenses for the second quarter of 2013 were $19.1 million compared to $17.6 million for the second quarter of 2012. This overall increase in operating expenses reflects an increase in general and admini
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , December 24, 2014 ... Report on Global Disposable Syringe Industry of ... its online business intelligence library. ... Disposable Syringe Industry is a professional and ... market.  For overview analysis, the report introduces ...
(Date:12/24/2014)... 23, 2014  The American Diabetes Association is ... for people with diabetes and that all people ... of statins, in keeping with recent changes to ... American College of Cardiology (ACC) and American Heart ... most recent changes to the Association,s annual revised ...
(Date:12/24/2014)... Dec. 23, 2014  Medical Science Liaisons play a ... link between the medical device industry and key stakeholders, ... the coming years as the device industry relies on ... to research by benchmarking firm, Best Practices, LLC, one ... important edge is by harnessing new technology to enable ...
Breaking Medicine Technology:World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4Role of Medical Science Liaisons Evolving in Medical Device Sector 2
... Newport Corporation (Nasdaq: NEWP ) today announced that it has ... to Dynasil Corporation (OTC Bulletin Board: DYSL), a provider of technology, ... markets. , , ... Hilger, based in Margate, UK, manufactures and sells a variety of ...
... N.Y. , July 20 As of ... standards applicable to devices that measure A1C (or glycated ... (NGSP) changed to +/-0.75% A1C, 95% CI, 4-10.0% A1C ... SELFCHECK devices, submits for annual NGSP certification each June ...
Cached Medicine Technology:Newport Corporation Completes Sale of Hilger Crystals to Dynasil Corporation 2Newport Corporation Completes Sale of Hilger Crystals to Dynasil Corporation 3New Standard of National Glycohemoglobin Standardization Program 2New Standard of National Glycohemoglobin Standardization Program 3
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is ... developing, producing and marketing of a series of induction ... their new series of induction brazing equipments . ... induction brazing refers to the joining of ... and heat. The manager says that there are fundamental ...
(Date:12/25/2014)... 2014 The report “Nintedanib (Colorectal ... focuses on the current treatment landscape, unmet needs, ... cancer market. Stivarga is a drug which is ... cancer. Boehringer Ingelheim is developing nintedanib (BIBF-1120), an ... refractory CRC in the US, Europe, and Japan. ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company ... collection of discounted prom dresses, most of which are ... of the company, the promotion is valid until Jan. ... expand the UK market. , The prom dresses in ... and styles: A-line strapless, empire strapless chiffon, one shoulder, ...
(Date:12/25/2014)... Miami, FL (PRWEB) December 25, 2014 When ... often find themselves in a frenzy to get rid of ... classroom. But families in Coral Gables now have the solution ... its second salon clinic location, Lice Troopers provides full spectrum ... in the Coral Gable area, including Sunset, Key Biscayne, Brickell, ...
(Date:12/25/2014)... -- Among early stage breast cancer patients who undergo ... percent will eventually develop leukemia as a result of ... comes from a review of more than 20,000 breast ... suggests that the risk for developing treatment-related leukemia, though ... "The frequency of bone marrow cancers such as ...
Breaking Medicine News(10 mins):Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... Second quarter highlights: ... - ... - 137% Operating Profit Increase ... Benefit of $377 k adds 1 cent to E.P.S., CHICAGO, May 14 The Female Health Company,(Amex: FHC ) which ...
... substitute market to reach almost ... Group, WALTHAM, Mass., May 14 With the ... first,off-the-shelf bone graft substitute (BGS) product to incorporate viable,stem ... other,innovative products will drive the BGS market to $1.9 ...
... 2 to 3 times faster, dramatically boosting survival ... they have dramatically increased the survival rate for people ... fine-tuning the dosage and timing for administering the clot-busting ... what,s usually an 80 percent death rate in patients ...
... Rosenthal, founder and primary teacher, hits five cities in one ... ... Joshua Rosenthal, founder and primary,teacher of the Institute for Integrative Nutrition, ... U.S. cities,between May 17 and June 14. He will demystify the confusion ...
... May 14 Green tea consumption may,promote cancer-preventive effects ... the medical treatment of some kinds of cancer, according ... Therapies in Health and,Medicine, on newsstands now., In ... potential,in human stomach and colon cancers, 6 cancerous and ...
... VEGAS, May 14 More than 2,000 physicians,researchers, Wall ... Bay Resort for THE Aesthetic Show, May 30 - ... aesthetic educational,program ever assembled in the U.S., this unique ... a $34 billion global market,for aesthetic treatments., "THE ...
Cached Medicine News:Health News:The Female Health Company Reports 267% Increase in Second Quarter Earnings 2Health News:The Female Health Company Reports 267% Increase in Second Quarter Earnings 3Health News:The Female Health Company Reports 267% Increase in Second Quarter Earnings 4Health News:The Female Health Company Reports 267% Increase in Second Quarter Earnings 5Health News:The Female Health Company Reports 267% Increase in Second Quarter Earnings 6Health News:The Female Health Company Reports 267% Increase in Second Quarter Earnings 7Health News:The Female Health Company Reports 267% Increase in Second Quarter Earnings 8Health News:The Female Health Company Reports 267% Increase in Second Quarter Earnings 9Health News:NuVasive Acquires First Stem Cell Bone Graft Substitute 2Health News:NuVasive Acquires First Stem Cell Bone Graft Substitute 3Health News:Clot-Busting Treatment Improves Bleeding Stroke Outcomes 2Health News:Institute for Integrative Nutrition Begins Road Tour 2Health News:Study Suggests Green Tea May Support the Medical Treatment of Stomach and Colon Cancer 2Health News:THE Aesthetic Show Advances $34 Billion Market 2Health News:THE Aesthetic Show Advances $34 Billion Market 3
... mm applier contains 20 titanium clips in the ... in the L size. The appliers are designed ... Auto Suture trocar sleeves, or larger sized trocar ... introduction of the ENDO CLIP clip applier through ...
... The Tissue Lock Clip is designed with ... superior on-vessel clip retention and improved hemostasis., ... design has a 20 percent greater angle ... placement., ,The Reflex® ELC has an ...
Insert only, Pilling-Weck small clip size...
Insert only, Ethicon, medium clip size...
Medicine Products: